Breaking News

BioStem Technologies to Acquire Auxocell Labs Assets

Assets provide expertise and resources to enhance manufacturing capabilities for a wide range of regenerative medicine products.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BioStem Technologies Inc. has entered into an agreement to acquire the majority assets of Auxocell Laboratories, Inc., a solid tissue processing equipment manufacturer.   Auxocell is the inventor and manufacturer of the Auxocell solid tissue processing device (AC:Px), a single-use, sterile processing system. The AC:Px can be used to produce a wide range of regenerative medicine products from a variety of solid tissues such as umbilical, placenta, adipose and deceased donor organs where a match...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters